MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--DNAnexus, Inc., a pioneer in cloud-based DNA data management and analysis solutions, today announced the appointment of Arthur Cole, PhD, as General Manager, Europe. Cole is a senior commercial executive who brings more than three decades of healthcare industry experience to DNAnexus. Based in the United Kingdom, Cole will be responsible for the company’s rapidly growing marketing, sales and business development activities across the European market.
“Arthur’s distinguished leadership career with commercial healthcare organizations in Europe makes him a clear choice for this vital role,” said Richard Daly, CEO of DNAnexus. “He is well respected within the European pharmaceutical, biotechnology and diagnostics markets and his experience will be an important asset to the company as we expand our presence in the region.”
A longtime member of the European healthcare industry, Cole joins DNAnexus from management consulting firm Debon Strategic Partners, where he was a managing partner providing strategic analysis, business planning and interim management services to biotechnology and molecular diagnostics companies. Prior, he was executive vice president at Visible Genetics where he led the company in Europe to a dominant position in DNA sequence-based HIV antiretroviral drug resistance testing before the company was acquired by Bayer Diagnostics. He also held a number of senior leadership positions during more than 13 years with Pharmacia Biotech including managing the company’s global commercial operations and leading the strategic planning process during a turn-around period in the company’s history. Cole earned his PhD in biochemistry from Charing Cross Hospital Medical School, University of London.
“The use of genomic data in clinical settings is an exciting medical advance that has created a pressing need for specialized technology infrastructures that can manage the demands of increasingly sophisticated data analysis pipelines,” said Cole. “DNAnexus excels in combining cloud computing infrastructure with scalable systems design and advanced bioinformatics, and I look forward to working with them to bring this technology to the many European organizations engaged in DNA-based medicine and biotechnology.”
The DNAnexus platform is a configurable API-based infrastructure that enables genomic R&D enterprises to easily expand their data analysis and storage infrastructure needs into the cloud and transform large capital expenditures into transparent operating expenses. Using DNAnexus, labs of any size can build and run their data analysis apps and workflows from anywhere in the world and work securely and compliantly with research and clinical collaborators.
For more information, please visit www.DNAnexus.com.
DNAnexus is powering the genomics revolution with a technology platform that combines cloud computing infrastructure with scalable systems design and advanced bioinformatics. The DNAnexus team is made up of experts in software, computational biology, and genetics who are on a mission to establish the DNAnexus platform as the core of a growing ecosystem of scientific and clinical research and diagnostic efforts in personalized medicine. For more information please visit https://dnanexus.com.